echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Officially released! In large-scale randomized controlled trials, the cheap drug cedriceon reduced the mortality rate of patients with new crowns (with invasive ventilation) by more than 30%.

    NEJM: Officially released! In large-scale randomized controlled trials, the cheap drug cedriceon reduced the mortality rate of patients with new crowns (with invasive ventilation) by more than 30%.

    • Last Update: 2020-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Due !---- to the rapid increase in new cases, coviral disease (COVID-19) quickly attracted global attention in 2019, with the pathogen identified as SARS-CoV-2So far today (July 18), according to real-time statistics released by Johns Hopkins University, there have been more than 14.24 million confirmed cases of new pneumonia worldwide, with 600,000 deathsthese numbers are updated daily and are expected to increase furthersevere COVID-19 pathophysiological characteristics are mainly acute pneumonia process, with a wide range of radiological opacity, and in the autopsy, diffuse alveoli injury, inflammatory immersion and microvascular thrombosisin other severe viral pneumonias, such as highly pathogenic avian influenza, SARS and seasonal influenza, the host's immune response is considered to play a key role in the pathophysiological effects of organ failurein severe Covid-19, inflammatory organ damage may occur, with significantly higher levels of inflammatory markers in one group of patients, including C-reactive protein, ferritin, interleukin-1, and interlemic-6has proposed several treatments to reduce inflammatory organ damage from viral pneumonia, but the value of glucocorticoids has been widely debatedAlthough a small trial reported improved clinical outcomes in patients with Covid-19 treated with meldonium, there is no reliable evidence of large-scale randomized clinical trials, which means that the effectiveness of glucocorticoids in Patients WithCovid-19 is uncertainJuly 17, 2020, the RECOVERY team published a research paper entitled "Dexamethasone in Patients with Covid-19 - Preliminary Report" published online in THE world's leading medical journal NEJMthe study reported preliminary results of a controlled, open label randomized assessment (RECOVERY) trial in Covid-19 in Dexametason in patients hospitalizeda total of 2,104 patients were assigned to dexamethasone and 4,321 patients received routine careoverall, 482 patients in the Dexametason group (22.9%) and 1110 patients in the routine care group (25.7%) died within 28 days of the random groupingThe proportion ofmortality and the differences between absolute groups varied significantly depending on the level of respiratory support that patients received at random groupingsthe incidence of death in the dexamethasone group was lower than in the conventional care group (29.3% vs41.4%) in patients receiving invasive mechanical ventilation, and those treated with oxygen were lower than those who did not have invasive mechanical ventilation (23.3% vs26.2%) in general, the use of dexamethasone reduced the mortality rate by 28 days in patients who were treated with non-breathing support compared to those who were not receiving respiratory support, and in patients who were randomly treated with invasive mechanical ventilation or oxygen-only treatment .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.